Dr. Stephen Nicholls and Dr. C. Michael Gibson Discuss: SURPASS-CVOT — Once-weekly Tirzepatide versus Dulaglutide for Heart Failure Outcomes in Patients with Type 2 Diabetes, ASCVD, and History of Heart Failure (pre-specified analysis of the SURPASS-CVOT Randomized Clinical Trial)